



VASUDHA PHARMA CHEM LIMITED

Contributing to Affordable HealthCare ...

Exports
90+
COUNTRIES



BRAZIL

MEXICO

CANADA

EUROPE

JAPAN

USA

MIDDLE EAST

INDIA

CHINA



DIGITAL CATALOGUE

ACCREDITATION



www.vasudhapharma.com

Vasudha Pharma Chem Limited (VPCL) was founded by Sri. **M.V.Rama Raju, Chairman & Managing Director, (CMD)** in 1994. Commenced commercial production in the year 1996. The organisation is involved in the manufacturing of Piperidone & Piperidine derivatives, Intermediates, APIs and Pellets. The manufacturing facilities of the company have been audited by several international regulatory authorities: USFDA, EDQM, PMDA, ANVISA COFEPRIS (Mexican MOH), Korean FDA, Russian FDA, NMPA, CANADA and WHO GMP.

M V Rama Raju – Chairman & Managing Director

- Founder of “Vasudha Foundation” (2004)
- VRRV Family Vasudha Foundation (Sec. 8. Co.), 2024
- Trustee & Executive Committee Member Kasturba Gandhi National Memorial Trust (Indore, INDIA)

A post graduate in Organic Chemistry with around 41 years of rich experience in the manufacture of Active Pharmaceutical Ingredients (APIs). He is a technocrat in the Pharmaceutical Industry and started his career in the South India Research Institute (SIRIS), 1972-76. Arvind Chemicals in 1976 for manufacturing of intermediates and Hyfabs in 1979 for the fabrication of chemical equipment. He was also founder and Managing Director of Hicel Pharma (P) Ltd, manufacturing Analgin during 1984-89. Finally he established Vasudha Pharma Chem Limited (VPCL) in 1994-95 and he has been the Managing Director of the organization since inception. Present stature and reputation of the organization is because of his vision, perseverance, active involvement in production, product development, marketing strategies, capacity expansion and upgradation of facilities to cGMP standards.

Vasudha Pharma Chem Limited (VPCL) major milestones are listed below :

Major Milestones of VPCL Unit - I

1994 : Established
1997 : Drug License received from DCA, Telangana State, India.
2003 : WHO GMP Certified.
2013 : EU-WC Grant from CDSCO, Delhi.

Since Established :

- Inspected by US FDA , Mexican MOH (COFEPRIS), MFDS, EU-WC received from CDSCO - India, PMDA EDQM, RUSSIAN GMP,
- Eco Vadis CSR rating Silver level (Nov, 2018), Bronze level (Oct, 2020), Silver level (Apr, 2022)
- 2021: EDQM (REAL TIME REMOTE INSPECTION)
- 2022: ISO14001:2015; 45001:2018
- 2022: Process Safety Management Program (PSM) introduced and under implementation
- 2025: Inspected by USFDA from March 10th to 14th

Major Milestones of VPCL Unit - II

2007 : Commenced the Operations.
2007 : Drug License received from DCA, Andhra Pradesh State, India.
2009 : WHO GMP Certified.
2013 : EU-WC Grant from CDSCO, Delhi

Since Established :

- Inspected by USFDA, KFDA, Mexican MOH (COFEPRIS), PMDA, EDQM, ANVISA
- 2021 : ISO 14001:2015; 45001:2018, Eco Vadis CSR rating - Bronze level (Nov, 2021),
- 2020 : PMDA, Japan accreditation received for Domperidone and Domperidone Maleate.
- 2022 : Process Safety Management Program (PSM) introduced and under implementation
Renewal of EU-WC from CDSCO, India, Inspection held from 7th & 8th April 2022.
- 2022 : NDA of Uganda inspected in the month of 30th & 31st May 2022 and Certificate received in the month of Jan 2023
- 2023 : Received EDQM Certificate
- 2024 : Eco Vadis CSR Rating : Bronze level Published on 29-05-2024 valid until 29-05-2025.
: Approved by USFDA from September 9th to 13th.
: Approved by ANVISA from October 28th to November 1st.
- 2025 : Inspected by CFDA from February 24th to 28th.



Major Milestones of VPCL Unit - III

2011 : Commenced the Operations.
2012 : Drug License received from DCA, Andhra Pradesh State, India.
2016 : WHO GMP Certified.
2014 : EU-WC Grant from CDSCO, Delhi

Since Established :

- Inspected by USFDA, KFDA, PMDA, ANVISA.
- 2017 ISO EMS 14001:2015BS Certified with ISO 45001 : 2018 Certified.
- Approved by US FDA & KFDA.
- 2021: Process Safety Management Program (PSM) introduced & under implementation
- 2023 : Successfully achieved ANVISA renewal ; ISO 14001: 2015 & ISO 45001 : 2015 renewal
- 2024 : Successfully achieved PMDA Certificate / EU-WC renewal for the API's

Major Milestones of VPCL Unit - IV

2016 : Commenced Operations
Received Drug License in 2016 License # : 11/VSP/AP/2016/F/R Valid up to 07/08/2026
2022 : Achieved WHO GMP Certificate in 2022 #: HMF07-14051/2017/2021-ADMIN-DCA- 02/05/2022
Valid up to 01/05/2025

Major Milestones of VPCL Unit - V

2019 : Commenced the Operations.
2019 : Drug License received from DCA, Andhra Pradesh State, India.
2021 : WHO GMP Certified.
2024 : EU-WC Grant from CDSCO, Delhi

Since Established :

- 2020 ISO EMS 14001: 2015 & ISO 45001: 2018 Certified.
- 2022: CEP certificate for the product of "Olmesartan Medoxomil" & "Process Safety Management" (PSM) introduced & Under implementation

Vasudha Pharma Chem Limited (VPCL) Accreditation :

India Ratings & Research (A Fitch Group Company) latest Rating on VPCL's Bank Facilities:

- Fund-based Working Capital Limits: IND A+/Stable/IND A1+
- Non-fund-based Working Capital Limits: IND A1+ with effect from 21-02-2025.
- DUNS & Bradstreet Rating : 5A2
- Government of India Accredited with 4 Star (★★★★) Export house certificate and also we are AEO T3 Certified Company.

Our Vision is to achieve sustainable & quality growth

- **Planet** : Want to be a responsible global citizen by helping & supporting ecological communities.
- **People** : VPCL to be a great work place, where human values are respected & people get inspired.
- **Portfolio** : Offering quality products across the globe satisfying the requirements of regulators and global pharma companies.
- **Productivity** : Achieving best productivity by continuous skill enhancement and technology upgradation.
- **Partners** : Creating a supportive network of customers & suppliers, jointly enhancing the value of the business.



ACTIVE PHARMACEUTICAL INGREDIENTS (APIs)

| Product Name | Specifications | DMF Status | CAS # |
|-----------------------------------|---------------------|-------------------------------|--------------|
| Amitriptyline HCl | IP/USP/BP/Ph.Eur/JP | USDMF/CEP/KDMF/CANADA | 549-18-8 |
| Aripiprazole | IP/USP/Ph.Eur | CEP Applied | 129-722-12-9 |
| Cisapride Monohydrate | USP | USDMF/ASMF | 260779-88-2 |
| Cinnarizine | Ph.Eur/USP/IP | CEP | 298-57-7 |
| Clopidogrel Bisulphate | IP/USP/BP/Ph.Eur/JP | USDMF/CEP | 120202-66-6 |
| Cyclobenzaprine HCl | USP/IP | USDMF/ASMF/KDMF/CADIFA/CANADA | 6202-23-9 |
| Cyproheptadine HCl | IP/USP/BP/Ph.Eur | USDMF/CDMF/ CEP Applied | 41354-29-4 |
| Dabigatran Etxilate Mesylate | Ph.Eur/USP | DMF / CEP Applied | 872728-81-9 |
| Desloratadine | USP/Ph.Eur/BP | USDMF/CEP/KDMF/CADIFA/CDMF | 100643-71-8 |
| Diatrizoic Acid | USP | USDMF | 117-96-4 |
| Diatrizoic Acid Dihydrate | USP/EP/IP | USDMF | 50978-11-5 |
| Diatrizoic Sodium | IP/USP | USDMF | 737-31-5 |
| Diatrizoic Meglumine | USP/IP | USDMF | 131-49-7 |
| Dimethyl Fumarate | In-House | USDMF | 624-49-7 |
| Diltiazem HCl | USP/Ph.Eur/IP | USDMF / CEP Applied | 33286-22-5 |
| Domperidone | IP/Ph.Eur/BP/JP/CP | CEP/JDMF/KDMF/CDMF | 57808-66-9 |
| Domperidone Maleate | IP/BP/Ph.Eur | CEP/KDMF | 83898-65-1 |
| Donepezil HCl | IP/USP/JP/Ph.Eur | JDMF | 120011-70-3 |
| Donepezil HCl Monohydrate | USP/Ph.Eur | USDMF/CEP Applied/KDMF | 884740-09-4 |
| Ebastine | Ph.Eur/BP/JP | CEP/BRAZIL DMF/ CADIFA | 90729-43-4 |
| Esomeprazole Magnesium Trihydrate | IP/USP/BP/Ph.Eur | USDMF/CEP/KDMF | 217087-09-7 |
| Febuxostat | In-House | DMF | 144060-53-7 |
| Fexofenadine HCl | IP/USP/BP/Ph.Eur/JP | USDMF/CEP/KDMF/CADIFA/CDMF | 153439-40-8 |
| Flurbiprofen | IP/USP/BP/Ph.Eur/JP | DMF | 5104-49-4 |
| Flunarizine Di HCl | USP/Ph.Eur/IP | CEP/KDMF/CDMF | 30484-77-6 |
| Itopride HCl | In-House/IP | KDMF/CDMF | 122892-31-3 |
| Itraconazole | USP/Ph.Eur/JP/CP | USDMF/CEP/JDMF/KDMF/CDMF | 84625-61-6 |
| Ketorolac Tromethamine | IP/USP/BP/Ph.Eur | USDMF/CEP/CADIFA | 74103-07-4 |
| Lacosamide | USP/Ph.Eur | CEP Applied | 175481-36-4 |
| Loperamide HCl | IP/USP/BP/Ph.Eur | USDMF/CEP/JDMF/CDMF | 34552-83-5 |
| Loratadine | USP/BP/Ph.Eur/IP | USDMF/CEP/CDMF/CADIFA/JDMF | 79794-75-5 |
| Losartan Potassium | IP/USP/BP/Ph.Eur/JP | USDMF/CEP/KDMF /CADIFA | 124750-99-8 |
| Mebeverine HCl | IP/IH/Ph.Eur/BP | CEP Applied | 2753-45-9 |
| Methoxyphenamine HCl | In-House | CDMF Applied | 93-30-1 |

Patented products available for R & D use only and are permitted under 35 USC 271 (e).

Patented products cannot be offered to the countries where patent law is in force.

Final responsibility lies with the buyer exclusively.



ACTIVE PHARMACEUTICAL INGREDIENTS (APIs)

| Product Name | Specifications | DMF Status | CAS # |
|-----------------------------------|---------------------|------------------------------|-------------|
| Mirabegron | Ph.Eur | USDMF/CEP Applied | 223673-61-8 |
| Nortriptyline HCl | IP/BP/USP/Ph.Eur/JP | USDMF/CEP/CADIFA | 894-71-3 |
| Oxatamide Anyhdrous | In-House | DMF/ASMF/JDMF | 60607-34-3 |
| Olmesartan Medoxomil | IP/USP/BP/Ph.Eur | USDMF/CEP | 144689-63-4 |
| Pantoprazole Sodium Sesquihydrate | IP/USP/BP/Ph.Eur | USDMF/CEP/KDMF/CADIFA/CANADA | 164579-32-2 |
| Pimozide | IP/USP/BP/Ph.Eur | USDMF/CEP | 2062-78-4 |
| Pimobendan | USP/Ph.Eur | DMF | 74150-27-9 |
| Pregabalin | IP/Ph.Eur/USP | USDMF/CEP/KDMF | 148553-50-8 |
| Quetiapine Fumarate | IP/USP/Ph.Eur/JP | USDMF/CEP | 111974-72-2 |
| Rivaroxaban | USP/Ph.Eur | USDMF/CEP | 366789-02-8 |
| Rupatadine Fumarate | IP/Ph.Eur/USP | USDMF/CEP/KDMF | 182349-12-8 |
| Tamsulosin HCl | IP/USP/BP/Ph.Eur | USDMF/CEP | 106463-17-6 |
| Telmisartan | IP/USP/BP/Ph.Eur | USDMF/CEP Applied | 144701-48-4 |
| Trazadone HCl | Ph.Eur/IP | CEP Applied | 25332-39-2 |
| Valsartan | USP/Ph.Eur/IP | DMF | 137862-53-4 |
| Vonoprazan fumarate | JP | DMF | 881681-01-2 |

UNDER DEVELOPMENT (APIs)

| Product Name | Specifications | DMF Status | CAS # |
|---------------------------|----------------|-------------------|-------------|
| Bempedaic acid | In-House | UNDER DEVELOPMENT | 738606-46-7 |
| Bepotastine Basilate | JP | | 190786-44-8 |
| Bilastine | IP | | 202189-78-4 |
| Dapagliflozin Propanediol | USP | | 960404-48-2 |
| Edoxaban Tosylate | In-House | | 480449-71-6 |
| Iopromide | USP/EP/BP/IP | | 73334-07-3 |
| Oxcarbazepine | USP/Ph.Eur | | 28721-07-5 |
| Piribedil | In-House | | 3605-01-4 |
| Sacubitril Sodium | USP | | 149690-05-1 |
| Ticagrelor | Ph.Eur/IP | | 274693-27-5 |

Patented products available for R & D use only and are permitted under 35 USC 271 (e).

Patented products cannot be offered to the countries where patent law is in force.

Final responsibility lies with the buyer exclusively.



INTERMEDIATES

| Product Name | Intermediate | CAS# |
|---------------------------------------|---|-------------|
| Alcaftadine | N-Methyl-4-chloro piperidine | 5570-77-4 |
| Amitriptyline HCl & Nortriptyline HCl | Dibenzosuberone | 1210-35-1 |
| | 3-(N,N, di methyl amino) propylchloride HCl | 5407-04-5 |
| Bepotastine Besilate | N-carbethoxy-4-hydroxypiperidine | 65214-82-6 |
| | α -(4-Chlorophenyl) pyridine -2-methanol | 27652-89-7 |
| | 2-((4-Chlorophenyl) (4-piperdinyloxy) methyl pyridine | 122368-54-1 |
| | 4-Hydroxypiperidine | 5382-16-1 |
| | 4-[(4-Chlorophenyl)-2-pyridylmethoxy]piperidine p-nitrobenzoic acid salt | 161558-45-8 |
| Brigatinib | 1-methyl-4-(piperidin-4-yl)-piperazine | 53617-36-0 |
| Cinnarizine and Flunarizine | 1-(Diphenyl methyl) piperazine | 841-77-0 |
| Cyclobenzaprine HCl | Dibenzosuberone | 2222-33-5 |
| | 3-(N,N Di methyl amino) propylchloride HCl | 5407-04-5 |
| Cyproheptadine HCl | Dibenzosuberone | 2222-33-5 |
| | N-Methyl-4-chloro piperidine | 5570-77-4 |
| Dabigatran Etxilate Mesylate | 3-[[[2-[[4-(Cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]pyridin-2-ylamino]propionic acid ethyl ester | 211915-84-3 |
| | N-[[2-[[[4-(Aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-beta-alanine ethyl ester | 429658-95-7 |
| | Ethyl 3-(((2-(((4-(((hexyloxy) carbonyl) amino) iminomethyl) phenyl) amino)\methyl)-1-methyl-1H-benzimidazol-5-yl)\carbonyl)(pyridin-2-yl)amino) propanoate | 211915-06-9 |
| Domperidone | 1-(3-Chloropropyl)-1,3-dihydro-1H-benzimidazol-2-one | 62780-89-6 |
| | 5-Chloro 1,3 dihydro -1- (4-piperidinyl) -2H- benzimidazol - 2 -one | 53786-28-0 |
| Donepezil | 4-[(5,6-Dimethoxy-1-indanon-2-yl) methyl] piperidine | 120014-30-4 |
| | 5,6-dimethoxy-2-(pyridine-4-yl)-methylene-indan-1-one | 4803-74-1 |
| Donepezil (BASE) | (2RS)-2-[(1-Benzylpiperidin-4-yl)-5, 6-dimethoxy-2, 3- dihydro-1H-inden-1-one | 120014-06-4 |
| Ebastine | 4-Tert butyl-4-chlorobutyrophenone | 43076-61-5 |
| Eprosartan | 2-Butyl-1H-imidazole-5-carboxaldehyde | 68282-49-5 |
| Febuxostat | Ethyl 2-(4-hydroxyphenyl)-4-methyl thiazole-5-carboxylate | 161797-99-5 |
| | Ethyl 2-(3-formyl-4-hydroxyphenyl)-4-methylthiazole-5-carboxylate | 161798-01-2 |
| | Ethyl 2-(3-cyano-4-hydroxyphenyl)-4-methylthiazole-5-carboxylate | 161798-02-3 |
| | Ethyl-2-(3-Formyl-4-isobutoxy phenyl)-4-methyl-1,3-thiazole-5-carboxylate | 161798-03-4 |
| | Ethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylate | 160844-75-7 |
| Flunarizine Di hydrochloride | 1-[bis(4-fluorophenyl)methyl]piperazine | 27469-60-9 |
| Gadobutrol (Cyclen intermediate) | 1,4,7,10-Tetraazacyclododecane | 294-90-6 |
| Golvatinib & Gilteritinib | 1-N-Methyl-4-(4-piperidin-4-yl)-piperazine | 53617-36-0 |
| Haloperidol | 4-Chloro-4'-fluoro-butyrophenone | 3874-54-2 |
| | 4-(4-Chlorophenyl)-4-hydroxy piperidine | 39512-49-7 |
| Indoramin hydrochloride | 4-Benzamido piperidine | 194423-17-1 |
| Ketotifen | N-Methyl-4-chloro-piperidine | 5570-77-4 |
| Linagliptin | (R)-3-(boc-amino) piperidine | 309956-78-3 |
| | (R)-3-Piperidinamine dihydrochloride | 334618-23-4 |



INTERMEDIATES

| Product Name | Intermediate | CAS# |
|----------------------------|--|--------------|
| Loperamide HCl | 4-(4-Chlorophenyl)-4-hydroxy piperidine | 39512-49-7 |
| | N,N-Dimethyl(tera hydro-3,3-diphenyl)-2-furylidene ammonium bromide (furaninium bromide) | 37743-18-3 |
| | α,α -Diphenyl- γ -butyrolactone | 956-89-8 |
| | 4-Bromo-2-2-diphenylbutyric acid | 37742-98-6 |
| Loratadine & Desloratadine | 3-[2-(3-Chlorophenyl) ethyl]-2-cyano pyridine | 31255-57-9 |
| | 8-Chloro-5,6 dihydro(11H)-benzo[5,6] cyclohepta (1,2b) pyridine -11-one | 31251-41-9 |
| | 8 Chloro-11-[(N-methyl)-4-piperidylidene]-6, 11-dihydro-5H-benzo [5,6]cyclohepta (1,2b) pyridine (methyl loratadine) | 38092-89-6 |
| | {3-[2-(3-Chlorophenyl)ethyl]pyridine-2-yl}-(1-methyl piperidine-4-yl) (methanone HCl) | 119770-60-4 |
| | N-Methyl-4-chloro piperidine | 5570-77-4 |
| Losartan Potassium | 2-N-Butyl-4-chloro-1-[(2"-H tetrazol-5-yl)(1,1"- biphenyl)-4yl)methyl]-1H imidazole-5-methanol(losartan base) | |
| | 2-Butyl-4-Chloro-5-Formylimidazole (BCFI) | 11479-26-4 |
| | | 83857-96-9 |
| Mirabegron | (R)-N-(4-nitrophenethyl)-2-hydroxy-2-phenylacetamide | 521284-19-5 |
| | (R)-2-(4-nitrophenethylamino)-1-phenylethanol.HCl | 521284-21-9 |
| | (R)-2-(4-aminophenethylamino)-1-phenylethanol | 521284-22-0 |
| Oxatomide | 1-(3-Chloropropyl)-1,3-dihydro-2H-benzimidazol-2-one | 62780-89-6 |
| | 1-(Diphenyl methyl) piperazine | 841-77-0 |
| Pemetrexed | 4-[2-(2-Amino-4,7-dihydro-4-oxo-1h-pyrrolo[2,3-d] Pyrimidin-5-yl)ethyl] Benzoic Acid | 137281-39-1 |
| Pimozide | 4-(2-Keto-1-benzimidazoliny)l piperidine | 20662-53-7 |
| | 1-Chloro-4,4-di (4-fluorophenyl)butane | 3312-04-7 |
| Prucalopride | 1-(3-Methoxy propyl) piperidine-4-one | 16771-85-0 |
| | 1-(3-Methoxypropyl)-4-Piperidinamine | 179474-79-4 |
| Rifabutin | 1-Isobutyl-4-piperidone | 72544-16-2 |
| Rivaroxaban | 4-[4-[(5S)-5-Phthalimidomethyl-2-oxo-3-oxazolidinyl]phenyl]-3-morpholinone | 446292-08-6 |
| | 4-(4-((S)-5-(Aminomethyl)-2-oxooxazolidin-3-yl) phenyl)morpholin-3-one HCl | 898543-06-1 |
| Ropivacaine | (S)-N-(2,6-Dimethylphenyl)piperidine-2-carboxamide | 27262-40-4 |
| Rupatadine Fumarate | 3-Chloromethyl-5-methyl pyridine HCl | 1007089-84-0 |
| Selexipag | 4-(Isopropylamino)butanol | 42042-71-7 |
| Tamsulosin | R-(-)-5-(2-Amino-propyl)-2-methoxy-benzenesulfonamide | 112101-81-2 |
| | 5-[2-[2-(2-Ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide | 106133-20-4 |
| Trazadone | [1,2,4]triazolo[4,3-a]pyridin-3-one | 6969-71-7 |
| | "1-(3-chlorophenyl)-4-(3-chloropropyl)piperazine hydrochloride" | 52605-52-4 |
| Vonoprazan Fumarate | 5-(2-Fluorophenyl)-1-(3-pyridinylsulfonyl)-1H-pyrrole-3-carboxaldehyde | 881677-11-8 |
| New Intermediate | N-(4-Amino-2-Cyanophenyl)-N,N-Dimethylmethanimidamide | 194423-17-1 |



PIPERIDONE AND PIPERIDINE DERIVATIVES

N-METHYL PIPERIDONE DERIVATIVES :

- N-Methyl-4-piperidone (1445-73-4)
- N-Methyl-4-hydroxypiperidine (106-52-5)
- N-Methyl-4-chloropiperidine (5570-77-4)
- N-Methyl-4-chloropiperidine HCl (5382-23-0)
- N-Methyl-4-aminopiperidine (41838-46-4)
- N-Carbethoxy-4-piperidone (29976-53-2)
- N-Carbethoxy-4-hydroxypiperidine (65214-82-6)
- N-Carbethoxy-4-aminopiperidine (58859-46-4)

N-BENZYL PIPERIDONE DERIVATIVES :

- N-Benzyl -4-piperidone (3612-20-2)
- N-Benzyl -4-hydroxypiperidine (4727-72-4)
- 4-Benzyl -4-hydroxypiperidine (51135-96-7)
- N-Benzyl -4-chloropiperidine (67848-71-9)
- N-Benzyl-4-aminopiperidine (50541-93-0)
- 4-(2-Keto-benzimidazolyl) piperidine (20662 -53-7)

SPECIALISED PIPERIDONE DERIVATIVES :

- 4-Piperidone ethylene ketal (177-11-7)
- 4-Hydroxypiperidine (5382-16-1)
- 4-Aminopiperidine (13035-19-3)
- 4-Piperidinopiperidine (4897-50-1)
- 1,4'-Bipiperidine dihydrochloride (4876-60 -2)
- N-Piperidin-4-ylbenzamide (33953-37-6)
- N-Isobutyl -4-piperidone (72544-16-2)
- 1-(4 -Chlorobenzhydryl) -piperazine (303-26-4)
- N-Ethyl-4-piperidone (3612-18-8)
- 1,3 -dimethyl -4-piperidone (4629 -80-5)
- (R)-(-)-3- Aminopiperidine dihydrochloride (334618-23-4)
- N-Propyl -4-piperidone (23133-37-1)
- 3-Chloromethyl-5-Methylpyridine Hydrochloride (1007089-84-0)

GRIGNARD REACTION PIPERIDONE DERIVATIVES

- 4-(4-Chlorophenyl)-4-hydroxypiperidine (39512-49-7)
- 4-(4-Bromophenyl) -4-hydroxypiperidine (57988-58-6)
- 4-Phenyl-4-hydroxypiperidine (40807-61-2)
- 4-Phenylpiperidine (771-99-3)

RESEARCH and DEVELOPMENT (R&D)

Our R&D centre is a state of Art facility (area 8475 sq.ft) with 23 number of modernist Fume Hoods, fully equipped with advanced analytical instruments, having 114 number of highly qualified scientific resources who have capacity to handle diverse projects simultaneously.

Key Capabilities of R&D:

- Fastrack "Process Development" and "Technology Transfer" to site
- Non-infringing process identification and IP landscaping
- DOE-QbD based process development as per ICH guideline (CQA and CPP assessment)
- Rapid, stability indicating "Analytical Method Development"
- Impurity mining, isolation and characterization followed by spike and purge study
- Efficient data integration and efficient trouble shooting
- Process Engineering Assessment (Failure Mode Effective Analysis)
- Process safety and 'HAZOP' study Assessment
- Polymorph study
- Proactive backward integration of raw materials

These core competencies reflect our commitment to excellence, innovation, and delivering high-quality pharmaceutical products and services to our clients.

Our focus on effective planning, resource allocation, and risk management ensures successful project execution



Pellets

| Enteric Coated (EC) | Composition W/W |
|---------------------|-------------------------------------|
| Duloxetine | 17%, 20% |
| Esomeprazole | 8.5%, 22.5%, 30% |
| Esomeprazole (MUPS) | 22.5% |
| Lansoprazole | 8.5% |
| Omeprazole | 7.5%, 8.5% |
| Pantoprazole | 15%, 16%, 20%, 22%, 22.5%, 30%, 40% |
| Rabeprazole | 10%, 15%, 20% |

| Immediate Release (IR) | |
|------------------------|------------------------------|
| Domperidone | 5.5%, 10%, 20%, 22.0%, 22.5% |
| Itraconazole | 20%, 22% |
| Orlistat | 50% |

| Sustained Release (SR) | |
|------------------------|--------------------|
| Diclofenac Sodium | 40% |
| Domperidone | 20%, 30% |
| Itopride HCl | 60% |
| Levosulpiride | 50% |
| Mebeverine HCl | 80% |
| Tamsulosin HCl | 0.2%, 0.12%, 0.16% |

| Under Development | Type | Composition W/W |
|---------------------------|------|------------------------|
| Chlorpheniramine Maleate | SR | 6.72%, 8% |
| Dabigatran Etxilate | IR | 35%, 40% |
| Dexlansoprazole | DR | 22.5% |
| Flurbiprofen | SR | 60% |
| Ketoprofen | SR | 60% |
| Levomilnacipran | SR | 38.71%, 38.83%, 39.21% |
| Mesalamine | ER | 60% |
| Metoprolol Succinate MUPS | SR | 60%, 66%, 58% |
| Pancreatin Pellets | EC | 60%, 70% |
| Peppermint oil Pellets | EC | 23% |
| Venlafaxine | ER | 33% |

Percentage of the Pellets can be customised as per market requirements.

CUSTOM SYNTHESIS and CONTRACT MANUFACTURING

VPCL offers long term Contract Manufacturing services right from strategic partnerships in development, validations, DMF filing and commercial manufacturing of Active Pharmaceutical Ingredients (APIs) / advanced intermediates to APIs. We have flexible business models to support various client needs:

- Process optimisation, technology transfer, validations and DMF filing followed by manufacturing upon commercialization
- Technology absorption, validations, DMF filing support and commercial manufacturing
- Technology absorption and commercial manufacturing



Progress in Environmental, Health, Safety and Sustainability (EHS)



VASUDHA PHARMA CHEM LIMITED



- ISO 45001:2018 & ISO 14001:2015 Certified
- Achieved Bronze medal Rating By “EcoVadis”
- Implementing Process Safety Management (PSM) system
- EHS Audits as per the PSCI guidelines.
- Best management award by Telangana State Govt in 2016 & 2023.
- Best management award by Andhra Pradesh State Govt om 2018.
- Achieved “A” rating by A.P.Factories Department (Score:93.5/100).
- Clean & Green and Safety precautions award by state body (TSIIC – 2017, 2018 & 2019)
- Continuously working on the Reduce, Reuse & Recycle policy.
- Achieved “C” rating by CDP (Carbon Disclosure Project) for 2023-24.
- Being regularly trained and nurtured on current EHS practises by top MNC’s.

VPCL Priorities

- Environment, Health and Wellness, Safety;
- Quality;
- Quantity.
- Sustainability

Environmental, Health & Safety

- VPCL is fully equipped with all kinds of necessary **Safety Equipment**.
- Periodic **Safety Training** programmes to all employees.
- **Occupational Health Centre** is equipped with all necessary medicines and equipment. Periodic **medical check-ups**.
- Personnel, trained on **First Aid**, are available in all the shifts.
- VPCL maintains **Green Belt** and plantation.
- VPCL actively encourages employees to meditate and celebrates world meditation day on 21st December every year.

EcoVadis Rating

| | | |
|-------------------|---|------------------------------------|
| VPCL - I | : | EcoVadis CSR rating - Bronze level |
| VPCL - II | : | EcoVadis CSR rating - Bronze level |
| VPCL - III | : | EcoVadis CSR rating - Bronze level |
| VPCL - V | : | EcoVadis CSR rating - Bronze level |
| SRCCCL | : | EcoVadis CSR rating - Bronze level |





VASUDHA FOUNDATION

78 A, Vengalrao Nagar, HYDERABAD 500038 India

Tel : 0091 40 44763666 Fax : 0091 40 44763636

With a desire to serve the society and to help the needy, Vasudha Foundation, was founded by Mr. MANTENA VENKATA RAMA RAJU and his family members in the year 2004.



Objectives of VASUDHA FOUNDATION

- Educational and medical assistance
- Helping hand to specially abled people
- Welfare of orphan, down trodden, old age, ill-fated women and children.
- Immediate help to the people in crisis at the time of natural calamities

Carries out its services through the following programmes :

- Akshara** (Education) : Programme designed to extend helping hand to poor students pursuing higher education like engineering, medicine, post graduate courses & Vocation Skills Development etc.
- Aarogya** (Health) : Programme designed to provide financial assistance for medical treatment to the poor and needy.
- Aashraya** (Shelter) : Programme designed to address the problems faced by the senior citizens and taking care of them during their sacred phase of Vruddhapy life (old age)
- Aadarana** (Care & Rehabilitation) : Programme designed to enable specially abled people to face the challenges in life and lead a normal life.
- Akshaya** (Socio-economic development relief during natural calamities) : Contributions to the Prime Minister's National Relief Fund or any other Fund Set up by the Central Government of the State Government for Socio-economic development, relief, welfare etc. Programme designed to stand forefront to extend helping hand to the people effected by natural calamities.
- Aparigraha** : Ensuring environmental sustainability, ecological balance, Animal welfare, agro forestry and conservation of natural resources.
- Samskruti** : Protection of National Heritage, Art & culture including setting up of public libraries, development of traditional arts and handicrafts. Promoting rural sports, national recognized sports and Olympic sports. Rural development projects. Supporting armed forces veterans, war widows and their dependants. Contributions to technology incubators approved by Central Government



Helping Students



Assistance to Seniors



Assistance to Old age home



Assistance to Old Age Home



Free Tailoring Training to women



Tailoring Machine's to poor women



www.vasudhapharma.com

Other Activities:

Planting saplings, Commissioning Water Purification Plants (600+) establishment of Schools, Colleges, Hospitals, Health Centers and Social Welfare Hostels, Promoting talent Arts & Sports, Providing training & distribution of Tailoring machine's to poor women.

| AKSHARA ₹ | AROGYA ₹ | AASHRAYA & AADARANA ₹ | AKSHAYA ₹ | APARIGRAHA ₹ | SAMSKRUTI ₹ |
|--------------|-------------|-----------------------------|--------------|-----------------|----------------|
| 1,33,97,500 | 1,30,35,004 | 88,18,120 | 12,00,000 | 4,75,000 | 22,35,000 |

*USD spent 2023-24 on the above programmes - \$ 470,888 (₹ 3,91,60,624)

Corporate Social Responsibility (CSR):

Enactment of Companies Act, 2013 by the Ministry of Corporate Affairs, Government of India was one of the world's largest experiments of introducing the CSR as a mandatory provision by imposing statutory obligation on Companies to take up CSR projects towards social welfare activities. The Corporate Social Responsibility (CSR) concept in India is governed by Section 135 of the Companies Act, 2013 ('Act'), Schedule VII of the Act and Companies (CSR Policy) Rules, 2014

As per National CSR Portal, VPCL is among the companies that spend more than the prescribed requirements mandated by the government.

| Financial Year | Companies that fulfill CSR | Our Position from the Top |
|----------------|----------------------------|---------------------------|
| 2022-23 | 13,571 | 401 |
| 2021-22 | 11,013 | 501 |
| 2020-21 | 9,935 | 576 |



(Sarve janah sukhino bhavanthu)

May everyone live happily

REGISTERED OFFICE:

78 A, Vengalrao Nagar, Hyderabad 500038, Telangana, India.

Phone : 0091-40-23711717

CORPORATE OFFICE:

Plot #: 120 and 121, 4th Floor, Jyothi Galaxy, Guttala Begumpet Village,
Kavuri Hills, Hyderabad 500033 Telangana, India.

Phone : 0091-40-4476 3666 / 2371 1718. Fax : 0091-40-4476 3636 / 2370 6696
Email ID : vasudha@vasudhapharma.com | Website : www.vasudhapharma.com

WORKS

- Unit I : Plot # 37/A, 38, 39 A & B, Phase I, IDA. Jeedimetla, Hyderabad-500055, Telangana, India
Unit II : Plot # 79, Jawaharlal Nehru Pharma City, Parawada, Anakapalli-531019 A.P, India
Unit III : Plot # 23, 24, Jawaharlal Nehru Pharma City, Parawada, Anakapalli-531019 A.P, India
Unit IV : Plot # 1, Jawaharlal Nehru Pharma City, Parawada, Anakapalli-531019, A.P, India
Unit V : Plot # 24, 24A & 24B, Atchutapuram, Rambili Mandal, Anakapalli-531011 A.P, India.

R&D CENTRE

Ramky Commercial Hub, Rd#13, JN Pharma City, Parawada,
Anakapalli-531019, Andhra Pradesh, INDIA.

www.vasudhapharma.com



MAY 2025

